Mersana Therapeutics, INC Form 4 insider transactions
Mersana Therapeutics' VP, Chief Accounting Officer, Ashish Mandelia, executed stock transactions involving the vesting of restricted stock units and subsequent sale to cover tax obligations.
Mersana Therapeutics' SVP, Chief Sci.&Tech. Officer, Timothy B. Lowinger, exercised restricted stock units and sold a portion of the shares to cover tax obligations.
Brian DeSchuytner, SVP, COO & CFO of Mersana Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
A Mersana Therapeutics executive sold 952 shares of common stock at $0.63 per share to cover tax obligations following the vesting of restricted stock units.
Form 4: Mersana Therapeutics Director Anna Protopapas Executes Stock Transactions Following RSU Vesting
Anna Protopapas, a director at Mersana Therapeutics, executed stock transactions including the acquisition of shares through RSU vesting and a subsequent sale to cover tax obligations.
Form 4: Mersana Therapeutics VP, Chief Accounting Officer, Ashish Mandelia, Reports Stock Transactions
Ashish Mandelia, VP and Chief Accounting Officer at Mersana Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Timothy B. Lowinger, SVP, Chief Sci.&Tech. Officer at Mersana Therapeutics, exercised stock options and sold shares to cover tax obligations.
Brian DeSchuytner, SVP, COO & CFO of Mersana Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
A Mersana Therapeutics executive sold 3,330 shares of common stock at $0.66 per share to cover tax obligations following the vesting of restricted stock units.
A Mersana Therapeutics executive, Mohan Bala, sold 3,253 shares at $0.66 each to cover tax obligations following the vesting of restricted stock units.
Director Lawrence M. Alleva of Mersana Therapeutics, Inc. received 12,521 stock options on January 2, 2025, in lieu of a cash retainer for director services.
EcoR1 Capital, LLC exchanged common stock for pre-funded warrants in Mersana Therapeutics, Inc., altering its beneficial ownership.
Mohan Bala, SVP and Chief Development Officer at Mersana Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units.
Brian DeSchuytner, SVP, COO & CFO of Mersana Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Alejandra Carvajal, SVP, Chief Legal Officer of Mersana Therapeutics, reports the sale of common stock to cover tax obligations related to the vesting of restricted stock units.
SVP, Chief Development Officer Mohan Bala reports the sale of Mersana Therapeutics (MRSN) stock to cover tax obligations after restricted stock units vested.
Ashish Mandelia, VP and Chief Accounting Officer of Mersana Therapeutics, reports the sale of common stock to cover tax obligations related to vested restricted stock units.
Form 4: Mersana Therapeutics SVP, Chief Sci.&Tech. Officer Timothy B Lowinger Reports Stock Transactions
Timothy B Lowinger, SVP, Chief Sci.&Tech. Officer of Mersana Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Director Lawrence M. Alleva of Mersana Therapeutics, Inc. received stock options in lieu of a cash retainer for director services.
CEO Martin H. Huber Jr. of Mersana Therapeutics exercised restricted stock units and sold a portion of the acquired shares to cover tax obligations, as disclosed in a recent SEC filing.
Director Lawrence M. Alleva receives stock options in Mersana Therapeutics in place of cash compensation for director services.
Director Andrew Hack acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Director Anna Protopapas acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
David M. Mott, a director at Mersana Therapeutics, acquired 55,000 stock options on June 11, 2024, according to a recent SEC filing.
Director Kristen Hege acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Director Allene M. Diaz acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Director Dere Willard H. acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Director Lawrence M. Alleva acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Director Lawrence M. Alleva of Mersana Therapeutics, Inc. acquired 3,996 stock options on April 1, 2024, in lieu of cash compensation for director services.